Lilly asks FDA to review weekly diabetes drug-WEB ONLY
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration has accepted their application for the once-a-week diabetes drug exenatide. Exenatide is the primary ingredient of Byetta, a treatment for type 2 diabetes. While Byetta is injected twice a day, the newer drug is intended […]